Wikisage, the free encyclopedia of the second generation, is digital heritage
XR-topiramate: Difference between revisions
Jump to navigation
Jump to search
(Created page with "'''Qudexy XR''' was approved by FDA on March 2014. It is effective on partial onset seisure once daily schedule<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409552/pdf/1...") |
mNo edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Qudexy XR''' was approved by FDA on March 2014. | '''Qudexy XR''' was approved by FDA on March 2014. | ||
It is effective on partial onset seisure once daily schedule<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409552/pdf/10.1177_1756285615578406.pdf A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures]</ref> | It is effective on partial onset seisure once daily schedule<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409552/pdf/10.1177_1756285615578406.pdf A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures]</ref> | ||
[http://www.epilepsybehavior.com/article/S1525-5050(16)00057-3/pdf Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes] | |||
<references/> | <references/> | ||
[[Category:Anticonvulsants]] | |||
Latest revision as of 23:53, 11 December 2016
Qudexy XR was approved by FDA on March 2014. It is effective on partial onset seisure once daily schedule[1]